Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Lymphoid 1

Conditions

Neoplasms 1Lymphoma, Follicular 1Hypertension 1Heart Failure 1

Interventions

pembrolizumab 1282Specimen Handling 927Carboplatin 836Magnetic Resonance Spectroscopy 834Cyclophosphamide 807Cisplatin 735Nivolumab 680Paclitaxel 635Radiotherapy 617Gemcitabine 580Biopsy 559Bevacizumab 485Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 361Fluorouracil 357atezolizumab 350durvalumab 340Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 319Blood Specimen Collection 317Standard of Care 311Pemetrexed 307Ipilimumab 303Radiation 287

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
sacubitril and valsartan sodium hydrate drug combination × 1 year × Clear all
NCT03872778 2026-04-30

NeoRay

Advanced Accelerator Applications

Phase 1/2 Completed
35 enrolled
Tumor-Agnostic

Neoplasms

NCT05194111 2026-03-13

TREAT-HF

Virginia Commonwealth University

Phase 1/2 Recruiting
53 enrolled

Heart Failure

NCT06236061 2026-01-13

Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Novartis

Phase 3 Completed
718 enrolled
Lymphoid

Hypertension, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡